SHARE NOW
BioCentriq launched their new LEAP™ Advanced Therapy Platform at the 29th International Society for Cell & Gene Therapy (ISCT) annual event with proven assets and expertise to help early-stage biotech companies effectively deliver to patients without compromising quality.
BioCentriq, a strategic CDMO specializing in cell therapy launched their new propriety LEAP™ Advanced Therapy Platform which leverage pre-existing assets and expertise to reduce process development and scale-up timelines by up to 75%. Details of the platform were presented at the 29th ISCT annual meeting.
“The LEAP™ platform is designed to help early-stage biotech companies prioritize speed in a very calculated and conscientious manner without compromising quality or introducing unnecessary risks,” said Haro Hartounian, Ph.D. and CEO and Founder of BioCentriq.
The assets leveraged include:
- Pre-Existing Master Batch Records
- Established SOPs
- Qualified Analytical Methods
- Trained Personnel
- Completed Aseptic Validation
- Proven and Reliable Supply Chain
- Phase Appropriate Quality System
- Fit-for-Purpose Facilities and Equipment
- Documented Training Programs
How are you enjoying this news article? Let us know your thoughts, here >>
Hartounian stated:
“In the current economic environment, biotech companies with promising candidates are under greater pressure than ever to demonstrate results quickly.”
Early-stage biotech companies that adopt the LEAP™ platform will be able to accelerate timelines, reduce risk, minimize up-front investment in process development and lower the cost of IND-enabling studies and clinical production.
The LEAP™ platform is offered in multiple modalities such as:
- LEAP-NK™
- LEAP-CAR™
- LEAP-TCELL™
- LEAP-TREG™
- LEAP-MSC™
BioCentriq presented results of recent studies that suggested that products used in conjunction with the LEAP-NK™ platform including BioCentriq’s propriety feeder cell lines can enhance the expansion of NK cells >12,000 fold and achieve desired scale using stirred-tank bioreactors.
“In addition to enhancing expansion of NK cells >12,000-fold, our propriety feeder cell lines produce a cell population that is potent and maintains desired surface activation markers,” explained Alex Klarer, VP of Business Strategy and Innovation. “The platform also scales the NK cell expansion process to a stirred tank bioreactor which allows for large-scale and cost-effective production.”
An overview of the new LEAP™ advanced therapy platform can be found here.
Source: BioCentriq Press Release; Image provided by and used with explicit permission from the BioCentriq team. For permission for re-use, please contact the BioCentriq team directly.
While we have you…
We are continuously working to better optimize our content for you, our audience. Let us know how we’re doing by ticking the box below, or send us your feedback directly to team@phacilitate.com.
